文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

与标准护理相比,专科虚拟病房中远程医疗辅助的急性心力衰竭门诊管理。

Telehealth-aided outpatient management of acute heart failure in a specialist virtual ward compared with standard care.

作者信息

Sankaranarayanan Rajiv, Rasoul Debar, Murphy Naomi, Kelly AnneMarie, Nyjo Siji, Jackson Carolyn, O'Connor Jane, Almond Peter, Jose Nisha, West Jenni, Kaur Rosie, Oguguo Chukwemeka, Douglas Homeyra, Lip Gregory Y H

机构信息

Liverpool University Hospitals NHS Foundation Trust, Aintree Hospital, Liverpool, UK.

Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.

出版信息

ESC Heart Fail. 2024 Dec;11(6):4172-4184. doi: 10.1002/ehf2.15003. Epub 2024 Aug 13.


DOI:10.1002/ehf2.15003
PMID:39138875
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11631251/
Abstract

AIMS: The aim of this propensity score matched cohort study was to assess the outcomes of telehealth-guided outpatient management of acute heart failure (HF) in our virtual ward (HFVW) compared with hospitalized acute HF patients. METHODS AND RESULTS: This cohort study (May 2022-October 2023) assessed outcomes of telehealth-guided outpatient acute HF management using bolus intravenous furosemide in a HF-specialist VW. Propensity score matching (PSM) was performed using logistic regression to adjust for potential differences in baseline patient characteristics between HFVW and standard care [Get With The Guidelines-HF score, clinical frailty score (CFS), Charlson co-morbidity index (CCI), NT-proBNP, and ejection fraction]. Clinical outcomes (re-hospitalizations and mortality) were compared at 1, 3, 6, and 12 months versus standard care-SC (acute HF patients managed without telehealth in 2021). Five hundred fifty-four HFVW ADHF patients (age 73.1 ± 10.9 years; 46% female) were compared with 404 ADHF patients (74.2 ± 11.8; P = 0.15 and 49% female) in the standard care-SC cohort. After propensity score matching for baseline patient characteristics, re-hospitalizations were significantly lower in the HFVW compared with SC (1 month-HFVW 8.6% vs. SC-21.5%, P < 0.001; 3 months-21% vs. 30%, P = 0.003; 6 months-28% vs 41%, P < 0.001 and 12 months-47% vs. 57%, P = 0.005) and mortality was also lower at 1 month (5% vs. 13.7%; P < 0.001), 3 months (9.5% vs. 15%; P = 0.001), 6 months (15% vs. 21%; P = 0.03), and 12 months (20% vs. 26%; P = 0.04). Multivariate logistic regression analysis showed that compared with standard care, HFVW management was associated with lower odds of readmission (1-month odds ratio (OR) = 0.3 [95% Confidence Interval CI 0.2-0.5], P < 0.0001; 3 month OR = 0.15 [0.1-0.3], P < 0.0001; 6-month OR = 0.35 [0.2-0.6], P = 0.0002; 12-month OR = 0.25 [0.15-0.4], P ≤ 0.001 and mortality (1-month OR = 0.26 [0.14-0.48], P < 0.0001; 3-month OR = 0.11 [0.04-0.27], P < 0.0001; 6-month OR = 0.35, [0.2; 0.61], P = 0.0002; 12-month OR = 0.6 [0.48; 0.73], P = 0.03. Higher GWTG-HF score independently predicted increased odds of re-hospitalization (1-month OR = 1.2 [1.1-1.3], P < 0.001; 3-month OR = 1.5 [1.37; 1.64], P < 0.0001; 6-month OR = 1.3 [1.2-1.4], P < 0.0001; 12-month OR = 1.1 [1.05-1.2], P = 0.03) as well as mortality (1-month OR = 1.21 [1.1-1.3], P < 0.0001; 3-month OR = 1.3 [1.2-1.4], P < 0.0001; 6-month OR = 1.2 [1.1-1.3], P < 0.0001; 12-month OR = 1.3 [1.1-1.7], P = 0.02). Similarly higher CFS also independently predicted increased odds of re-hospitalizations (1-month OR = 1.9 [1.5-2.4], P < 0.0001; 3-month OR = 1.8 [1.3-2.4], P = 0.0003; 6-month OR = 1.4 [1.1-1.8], P = 0.015; 12-month OR 1.9 [1.2-3], P = 0.01]) and mortality (1-month OR = 2.1 [1.6-2.8], P < 0.0001; 3-month OR = 1.8 [1.2-2.6], P = 0.006; 6-month OR = 2.34 [1.51-5.6], P = 0.0001; 12-month OR = 2.6 [1.6-7], P = 0.02). Increased daily step count while on HFVW independently predicted reduced odds of re-hospitalizations (1-month OR = 0.85[0.7-0.9], P = 0.005), 3-month OR = 0.95 [0.93-0.98], P = 0.003 and 1-month mortality (OR = 0.85 [0.7-0.95], P = 0.01), whereas CCI predicted adverse 12-month outcomes (OR = 1.2 [1.1-1.4], P = 0.03). CONCLUSIONS: Telehealth-guided specialist HFVW management for ADHF may offer a safe and efficacious alternative to hospitalization in suitable patients. Daily step count in HFVW can help predict risk of short-term adverse clinical outcomes.

摘要

目的:本倾向评分匹配队列研究旨在评估在我们的虚拟病房(HFVW)中,远程医疗指导下的急性心力衰竭(HF)门诊管理与住院急性HF患者相比的结局。 方法与结果:本队列研究(2022年5月至2023年10月)评估了在HF专科虚拟病房中使用静脉推注速尿进行远程医疗指导的门诊急性HF管理的结局。使用逻辑回归进行倾向评分匹配(PSM),以调整HFVW与标准治疗[遵循指南-HF评分、临床衰弱评分(CFS)、Charlson合并症指数(CCI)、NT-proBNP和射血分数]之间基线患者特征的潜在差异。比较了1、3、6和12个月时的临床结局(再住院和死亡率)与标准治疗-SC(2021年未接受远程医疗管理的急性HF患者)。554例HFVW急性失代偿性HF患者(年龄73.1±10.9岁;46%为女性)与标准治疗-SC队列中的404例急性失代偿性HF患者(74.2±11.8;P = 0.15,49%为女性)进行比较。在对基线患者特征进行倾向评分匹配后,HFVW的再住院率显著低于SC(1个月-HFVW为8.6%,SC为21.5%,P < 0.001;3个月-21%对30%,P = 0.003;6个月-28%对41%,P < 0.001;12个月-47%对57%,P = 0.005),1个月时的死亡率也较低(5%对13.7%;P < 0.001),3个月时(9.5%对15%;P = 0.001),6个月时(15%对21%;P = 0.03),12个月时(20%对26%;P = 0.04)。多因素逻辑回归分析显示,与标准治疗相比,HFVW管理与再入院几率较低相关(1个月优势比(OR)= 0.3 [95%置信区间CI 0.2 - 0.5],P < 0.0001;3个月OR = 0.15 [0.1 - 0.3],P < 0.0001;6个月OR = 0.35 [0.2 - 0.6],P = 0.0002;12个月OR = 0.25 [0.15 - 0.4],P ≤ 0.001)和死亡率(1个月OR = 0.26 [0.14 - 0.48],P < 0.0001;3个月OR = 0.11 [0.04 - 0.27],P < 0.0001;6个月OR = 0.35,[0.2;0.61],P = 0.0002;12个月OR = 0.6 [0.48;0.73],P = 0.03)。较高的GWTG-HF评分独立预测再住院几率增加(1个月OR = 1.2 [1.1 - 1.3],P < 0.001;3个月OR = 1.5 [1.37;1.64],P < 0.0001;6个月OR = 1.3 [1.2 - 1.4],P < 0.0001;12个月OR = 1.1 [1.05 - 1.2],P = 0.03)以及死亡率(1个月OR = 1.21 [1.1 - 1.3],P < 0.0001;3个月OR = 1.3 [1.2 - 1.4],P < 0.0001;6个月OR = 1.2 [1.1 - 1.3],P < 0.0001;12个月OR = 1.3 [1.1 - 1.7],P = 0.02)。同样,较高的CFS也独立预测再住院几率增加(1个月OR = 1.9 [1.5 - 2.4],P < 0.0001;3个月OR = 1.8 [1.3 - 2.4],P = 0.0003;6个月OR = 1.4 [1.1 - 1.8],P = 0.015;12个月OR = 1.9 [1.2 - 3],P = 0.01])和死亡率(1个月OR = 2.1 [1.6 - 2.8],P < 0.0001;3个月OR = 1.8 [1.2 - 2.6],P = 0.006;6个月OR = 2.34 [1.51 - 5.6],P = 0.0001;12个月OR = 2.6 [1.6 - 7],P = 0.02)。在HFVW期间每日步数增加独立预测再住院几率降低(1个月OR = 0.85[0.7 - 0.9],P = 0.005),3个月OR = 0.95 [0.93 - 0.98],P = 0.003和1个月死亡率(OR = 0.85 [0.7 - 0.95],P = 0.01),而CCI预测12个月的不良结局(OR = 1.2 [1.1 - 1.4],P = 0.03)。 结论:对于急性失代偿性HF,远程医疗指导的专科HFVW管理可能为合适的患者提供一种安全有效的替代住院治疗的方法。HFVW中的每日步数有助于预测短期不良临床结局的风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc42/11631251/66953b14592f/EHF2-11-4172-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc42/11631251/dbc25442f2ba/EHF2-11-4172-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc42/11631251/10b498d47c77/EHF2-11-4172-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc42/11631251/2be703ea0477/EHF2-11-4172-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc42/11631251/eddb0a477faa/EHF2-11-4172-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc42/11631251/c3f138a0339b/EHF2-11-4172-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc42/11631251/66953b14592f/EHF2-11-4172-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc42/11631251/dbc25442f2ba/EHF2-11-4172-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc42/11631251/10b498d47c77/EHF2-11-4172-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc42/11631251/2be703ea0477/EHF2-11-4172-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc42/11631251/eddb0a477faa/EHF2-11-4172-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc42/11631251/c3f138a0339b/EHF2-11-4172-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc42/11631251/66953b14592f/EHF2-11-4172-g001.jpg

相似文献

[1]
Telehealth-aided outpatient management of acute heart failure in a specialist virtual ward compared with standard care.

ESC Heart Fail. 2024-12

[2]
Comparative performance of risk prediction indices for mortality or readmission following heart failure hospitalization.

ESC Heart Fail. 2025-4

[3]
Dose of furosemide before admission predicts diuretic efficiency and long-term prognosis in acute heart failure.

ESC Heart Fail. 2022-2

[4]
The ADHF/NT-proBNP risk score to predict 1-year mortality in hospitalized patients with advanced decompensated heart failure.

J Heart Lung Transplant. 2013-12-16

[5]
Effect of a Telemedicine Model on Patients With Heart Failure With Reduced Ejection Fraction in a Resource-Limited Setting in Vietnam: Cohort Study.

J Med Internet Res. 2025-3-19

[6]
Design and baseline characteristics of SALT-HF trial: hypertonic saline therapy in ambulatory heart failure.

ESC Heart Fail. 2024-6

[7]
Weight telemonitoring of heart failure versus standard of care in a real-world setting: Results on mortality and hospitalizations in a 6-month nationwide matched cohort study.

Eur J Heart Fail. 2024-5

[8]
Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial.

J Am Coll Cardiol. 2017-6-27

[9]
Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure: A Substudy of the TRANSFORM-HF Randomized Clinical Trial.

JAMA Cardiol. 2024-2-1

[10]
Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.

Circ Heart Fail. 2013-12-18

引用本文的文献

[1]
Barriers and facilitators to the use of virtual wards: a systematic review of the qualitative evidence.

Int J Qual Health Care. 2025-7-4

[2]
Hospital-at-Home care for acute heart failure: Feasibility and safety pilot.

Neth Heart J. 2025-5

[3]
Economic evaluation of the Liverpool heart failure virtual ward model.

Eur Heart J Qual Care Clin Outcomes. 2025-3-3

本文引用的文献

[1]
Remote management of worsening heart failure to avoid hospitalization in a real-world setting.

ESC Heart Fail. 2023-12

[2]
Technology-enabled virtual ward for COVID management of the elderly and immunocompromised in Singapore: a descriptive cohort.

BMC Infect Dis. 2023-2-21

[3]
Virtual wards: a rapid evidence synthesis and implications for the care of older people.

Age Ageing. 2023-1-8

[4]
Outpatient versus inpatient intravenous diuretic therapy for heart failure in the United States.

Eur J Heart Fail. 2022-11

[5]
Performance of the heart failure risk scores in predicting 1 year mortality and short-term readmission of patients.

ESC Heart Fail. 2023-2

[6]
Multispecialty multidisciplinary input into comorbidities along with treatment optimisation in heart failure reduces hospitalisation and clinic attendance.

Open Heart. 2022-7

[7]
The Impact of Frailty and Comorbidities on Heart Failure Outcomes.

Card Fail Rev. 2022-3-21

[8]
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC.

Eur J Heart Fail. 2022-1

[9]
Ambulatory intravenous furosemide for decompensated heart failure: safe, feasible, and effective.

ESC Heart Fail. 2021-10

[10]
Hospital-at-Home Interventions vs In-Hospital Stay for Patients With Chronic Disease Who Present to the Emergency Department: A Systematic Review and Meta-analysis.

JAMA Netw Open. 2021-6-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索